Healthpeak lifts 2026 guidance after leasing gains and asset sales
Healthpeak raised its full-year outlook for the second time this year while using portfolio-sale proceeds to repay debt and authorise a US$500 million buyback.
Healthpeak Properties has raised its 2026 diluted earnings per share guidance to US$0.48–US$0.52, from US$0.46–US$0.50, according to figures reported by Yahoo Finance. Adjusted FFO guidance increased to US$1.73–US$1.77 after the company’s second-quarter results.
The healthcare real estate owner attributed the changes to outpatient leasing activity and growth at Janus Living. Outpatient medical occupancy rose to 90.7%, while lab occupancy reached 78.5%. Lab same-store net operating income nevertheless declined 3.2%.
Janus Living, in which Healthpeak holds a 73.6% stake, reported a 45% year-on-year increase in revenue to US$216 million. Adjusted EBITDA rose 34% to US$79 million. Outside investors own the remaining interest.
Healthpeak said it generated about US$1.4 billion from dispositions and loan repayments through 3 August. It repaid US$650 million of senior notes and about US$375 million of commercial paper, while its board authorised a US$500 million share-buyback programme.
The company’s net debt to adjusted EBITDAre stood at 4.7 times. The reported capital allocation was supported materially by portfolio sales and repayments, while the decline in lab same-store NOI showed that performance remained uneven across its operations.
